MRK1

114.35

+0.09%↑

SHL.DE

46.49

-3.73%↓

ARGX

512.6

-0.85%↓

FRE

43.08

-0.49%↓

ONC.US

239.97

+1.12%↑

MRK1

114.35

+0.09%↑

SHL.DE

46.49

-3.73%↓

ARGX

512.6

-0.85%↓

FRE

43.08

-0.49%↓

ONC.US

239.97

+1.12%↑

MRK1

114.35

+0.09%↑

SHL.DE

46.49

-3.73%↓

ARGX

512.6

-0.85%↓

FRE

43.08

-0.49%↓

ONC.US

239.97

+1.12%↑

MRK1

114.35

+0.09%↑

SHL.DE

46.49

-3.73%↓

ARGX

512.6

-0.85%↓

FRE

43.08

-0.49%↓

ONC.US

239.97

+1.12%↑

MRK1

114.35

+0.09%↑

SHL.DE

46.49

-3.73%↓

ARGX

512.6

-0.85%↓

FRE

43.08

-0.49%↓

ONC.US

239.97

+1.12%↑

Search

Sanofi SA

Geschlossen

BrancheGesundheitswesen

92.04 -1.26

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

92.03

Max

92.29

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.4B

1.9B

Verkäufe

3B

11B

KGV

Branchendurchschnitt

18.489

54.533

EPS

1.79

Dividendenrendite

4.27

Gewinnspanne

17.65

Angestellte

82,878

EBITDA

2.2B

2.8B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+25.66% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.27%

2.41%

Nächstes Ergebnis

31. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-17B

113B

Vorheriger Eröffnungskurs

93.3

Vorheriger Schlusskurs

92.04

Nachrichtenstimmung

By Acuity

36%

64%

113 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Sanofi SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Mai 2025, 12:02 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22. Mai 2025, 00:06 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Vigil Neuroscience for About $470 Million

5. Mai 2025, 11:29 UTC

Akquisitionen, Fusionen, Übernahmen

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- 2nd Update

5. Mai 2025, 09:09 UTC

Akquisitionen, Fusionen, Übernahmen

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- Update

5. Mai 2025, 07:25 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group to Buy Santander Assets in Poland for $7.91 Billion

21. Mai 2025, 23:33 UTC

Akquisitionen, Fusionen, Übernahmen

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21. Mai 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21. Mai 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21. Mai 2025, 23:23 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21. Mai 2025, 23:22 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21. Mai 2025, 23:20 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21. Mai 2025, 23:18 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

19. Mai 2025, 11:01 UTC

Market Talk

Diversified Exposure to European Banks Is Required -- Market Talk

15. Mai 2025, 11:04 UTC

Market Talk
Ergebnisse

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

13. Mai 2025, 12:53 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Natwest's Reported Santander UK Interest Seems Surprising -- Market Talk

13. Mai 2025, 10:23 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Santander's Geographic Refocusing Can Lift Earning Estimates -- Market Talk

13. Mai 2025, 08:58 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Any Sale of Santander UK Would Need Strong Justification -- Market Talk

12. Mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

8. Mai 2025, 17:55 UTC

Ergebnisse

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8. Mai 2025, 15:12 UTC

Ergebnisse

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

6. Mai 2025, 06:16 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Santander's Polish Business Disposal Is Attractive -- Market Talk

6. Mai 2025, 06:13 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Erste's Cash Deal for Santander Bank Polksa Seen as Positive -- Market Talk

5. Mai 2025, 14:11 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Erste Group Adds Exposure to Fast-Growing Polish Market, But Could Face Risk -- Market Talk

5. Mai 2025, 11:30 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Sale of Polish Business Strengthens Santander's Capital Position -- Market Talk

5. Mai 2025, 06:48 UTC

Akquisitionen, Fusionen, Übernahmen

Santander Intends to Take Full Ownership of Santander Consumer Bank Polska

5. Mai 2025, 06:48 UTC

Akquisitionen, Fusionen, Übernahmen

Santander Will Own 13% of Santander Polska Following Transaction

5. Mai 2025, 06:47 UTC

Akquisitionen, Fusionen, Übernahmen

Santander, Erste Enter Cooperation in Corporate & Investment Banking, Payments

5. Mai 2025, 06:46 UTC

Akquisitionen, Fusionen, Übernahmen

Santander Expects EUR2B Net Capital Gain From Deal

5. Mai 2025, 06:46 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group Says Profitability Is Set to Improve Significantly After Deal

5. Mai 2025, 06:45 UTC

Akquisitionen, Fusionen, Übernahmen

Erste Group Targets Return to Current Dividend Payout Range of 40-50% From 2026

Peer-Vergleich

Kursveränderung

Sanofi SA Prognose

Kursziel

By TipRanks

25.66% Vorteil

12-Monats-Prognose

Durchschnitt 115.787 EUR  25.66%

Hoch 127 EUR

Tief 95 EUR

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sanofi SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

15 ratings

11

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

91.3 / 96.1Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

113 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.